Introduction
Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic polyangiitis (EGPA) are the antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV). They are rare autoimmune conditions characterised by inflammation and sometimes necrosis of blood vessels unified by their association with antibody production towards antigens in the neutrophil cytoplasm. The two antigens of interest are proteinase 3 (PR3) and myeloperoxidase (MPO).
This review examines the evidence of the current state of play in the care of patients with this condition.
Standards of care

Early diagnosis and treatment
There are no diagnostic criteria for the diagnosis of AAV, there are no diagnostic tests for AAV, and there are no pathognomonic signs for AAV. But like all complex and life-threatening conditions, early diagnosis and treatment must be a goal. We know that damage is accrued over time and increasing damage has adverse prognosis. Specialist input cannot be provided without adequate number of specialists.
Standardized evaluation of patients with systemic vasculitis
In the absence of biomarkers, standardized evaluation of patients with AAV using clinical activity tools is recommended for documenting the full extent of the disease and for identifying new or resolving clinical signs on follow up. The Over the past 5 years, rituximab has become the standard of care for remission induction in young women, relapsing patients and those with urothelial cancers. The availability of this expensive drug has led to initiatives in the UK to recognise specialist centres which can supervise the use of this drug but more importantly advice on the care of the patients who need this drug. Methotrexate is falling out of favour. In clinical trial as well as in personal experience, it did not fulfil its early promise and we fear the same for mycophenolate mofetil -but time will tell! Using a piece of paper -BVAS v3 or BVAS/WG seems to be an archaic way of assessing disease activity, but for those of us who do it regularly, it is proving invaluable. It is a simple but effective way of making sure that all activity is accounted for and forces the clinician to make a judgement on every symptom and its relationship to the disease -activity, damage or coincidental. It needs training for its use to ensure that it is used appropriately.
We are making people live longer with complex drug regimens. This is now allowing us to see the havoc that the disease and its treatment can sometimes cause the body.
It should not be a surprise that patients with a vascular problem have greater risk of cardiovascular complications, especially when we use high-dose glucocorticoids to treat it. We need to be more vigilant about monitoring those patients when remission has been achieved.
EGPA has become an orphan amongst orphans. There is very little data to say anything meaningful about this disease. Most of what we have said above is based on data from GPA and MPA. It is time that the vasculitis community brought this condition into focus.
The remit of this paper was to address the need for a change in standards of care for AAV. The short answer to that question would be 'yes'. There is always need to change and evolve with increasing availability of evidence and we anticipate that this will continue to evolve rapidly -get on board and enjoy the ride.
